Cargando…

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated....

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Stephanie, Nolte, Ingo, Rumstedt, Katja, Sehn, Maximiliane, Raue, Jonathan Friedemann, Weiner, Franziska, Treese, Julia Sophie, Beyerbach, Martin, Bach, Jan-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467240/
https://www.ncbi.nlm.nih.gov/pubmed/34563187
http://dx.doi.org/10.1186/s12917-021-03014-5
_version_ 1784573346680143872
author Klein, Stephanie
Nolte, Ingo
Rumstedt, Katja
Sehn, Maximiliane
Raue, Jonathan Friedemann
Weiner, Franziska
Treese, Julia Sophie
Beyerbach, Martin
Bach, Jan-Peter
author_facet Klein, Stephanie
Nolte, Ingo
Rumstedt, Katja
Sehn, Maximiliane
Raue, Jonathan Friedemann
Weiner, Franziska
Treese, Julia Sophie
Beyerbach, Martin
Bach, Jan-Peter
author_sort Klein, Stephanie
collection PubMed
description BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180 days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test. RESULTS: NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11/15) and day 180 (12/15). Those animals treated with placebo were described as being more active at day 90 (2/15) and day 180 (5/15). CONCLUSIONS: Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-021-03014-5.
format Online
Article
Text
id pubmed-8467240
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84672402021-09-28 The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study Klein, Stephanie Nolte, Ingo Rumstedt, Katja Sehn, Maximiliane Raue, Jonathan Friedemann Weiner, Franziska Treese, Julia Sophie Beyerbach, Martin Bach, Jan-Peter BMC Vet Res Research BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180 days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test. RESULTS: NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11/15) and day 180 (12/15). Those animals treated with placebo were described as being more active at day 90 (2/15) and day 180 (5/15). CONCLUSIONS: Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-021-03014-5. BioMed Central 2021-09-25 /pmc/articles/PMC8467240/ /pubmed/34563187 http://dx.doi.org/10.1186/s12917-021-03014-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Klein, Stephanie
Nolte, Ingo
Rumstedt, Katja
Sehn, Maximiliane
Raue, Jonathan Friedemann
Weiner, Franziska
Treese, Julia Sophie
Beyerbach, Martin
Bach, Jan-Peter
The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title_full The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title_fullStr The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title_full_unstemmed The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title_short The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
title_sort effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467240/
https://www.ncbi.nlm.nih.gov/pubmed/34563187
http://dx.doi.org/10.1186/s12917-021-03014-5
work_keys_str_mv AT kleinstephanie theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT nolteingo theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT rumstedtkatja theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT sehnmaximiliane theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT rauejonathanfriedemann theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT weinerfranziska theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT treesejuliasophie theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT beyerbachmartin theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT bachjanpeter theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT kleinstephanie effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT nolteingo effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT rumstedtkatja effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT sehnmaximiliane effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT rauejonathanfriedemann effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT weinerfranziska effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT treesejuliasophie effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT beyerbachmartin effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy
AT bachjanpeter effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy